TG Therapeutics, Inc.
Every calculator, already run for TGTX
Open the full toolkit →You have the numbers on TGTX. Get the argument.
A written report on which of these readings actually decide the outcome for TG Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering TGTXAnalyst Price Target Disagreement for TG Therapeutics, Inc.
Wall Street's bull case implies +51% from the current price; the bear case implies -63%. A 114% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TGTX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK…
TGTX — frequently asked
Is TGTX a buy right now?
Wall Street's consensus rating on TG Therapeutics, Inc. is none across 8 analysts, with a mean price target of $69.71 (+23% vs. the current $56.87). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is TGTX overvalued?
TGTX trades at 20.8x trailing earnings, against a DCF fair value of $5 per share. The current price implies 40% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is TGTX's next earnings date?
TG Therapeutics, Inc. is next scheduled to report earnings around Nov 2, 2026. A full TGTX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for TG Therapeutics, Inc.?
Analysts covering TG Therapeutics, Inc. (TGTX) range from a bear-case target of $21.00 to a bull-case high of $86.00, with a mean consensus target of $69.71 across 7 analysts. The spread of $65.00 (114% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare TG Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For TG Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TGTX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on TG Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.